Journal of the American Academy of Child & Adolescent Psychiatry
ArticlesCase Study: Caudate Glutamatergic Changes With Paroxetine Persist After Medication Discontinuation in Pediatric OCD
Section snippets
METHOD
This 8-year-old girl had a normal vaginal delivery at full-term and achieved all developmental milestones. She presented with a 4-month history of OCD manifested by contamination, scrupulosity, religious and moral preoccupation, as well as recurrent, intrusive violent and sexual images coupled with fear of blurting out obscenities. Compulsions included hand-washing, excessive showering and cleaning, hoarding behaviors, and ritualistic rereading and rewriting. These symptoms significantly
RESULTS
The patient experienced a significant reduction in OCD symptoms with paroxetine treatment; her CY-BOCS score had decreased by 17 points, from 27 before treatment to 10 after 8 weeks (30 mg/day) and 12 weeks (40 mg/day) of treatment (Fig. 2). The patient was then maintained on paroxetine 40 mg/day for 14 months, with a CY-BOCS score of 4 recorded.
The treatment team, the patient, and her mother then attempted to discontinue the patient's paroxetine by decreasing the medication by 10 mg every 2
DISCUSSION
Caudate Glx concentration was seen to undergo a striking decrease in relation to paroxetine therapy and OCD symptom remission, and this decrease in Glx was maintained 3 months after medication discontinuation. These results suggest that a reversible glutamatergically mediated striatal dysfunction in pediatric OCD may serve as a pathophysiological and treatment response marker. Although direct clinical application on the basis of a single case study is limited, it illustrates how treatment
REFERENCES (14)
- et al.
N-acetyl- L -aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain (review)
Neurosci Biobehav Rev
(1989) - et al.
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity
J Am Acad Child Adolesc Psychiatry
(1989) - et al.
Functional anatomy of the basal ganglia, I: the cortico-basal ganglia-thalamo-cortical loop
Brain Res
(1995) - et al.
Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine
J Am Acad Child Adolesc Psychiatry
(2000) - et al.
Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity
J Am Acad Child Adolesc Psychiatry
(1997)
Cited by (59)
<sup>1</sup>H magnetic resonance spectroscopy suggests neural membrane alteration in specific regions involved in obsessive-compulsive disorder
2017, Psychiatry Research - NeuroimagingDisorders of Brain Development: Understanding Childhood Psychopathology
2016, Positive Mental Health, Fighting Stigma and Promoting Resiliency for Children and AdolescentsFronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: A review of magnetic resonance spectroscopy studies
2015, Neuroscience and Biobehavioral ReviewsEffects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder
2013, Journal of Psychiatric ResearchA critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder
2013, Biological PsychiatryCitation Excerpt :Five studies found increased tNAA levels in certain brain regions (27,32–35), but only one of these (33) found increased tNAA in a CSTC region (left rostral ACC), which then decreased significantly after 12 weeks of CBT. In contrast, another study found significantly increased left caudate tNAA after CBT (36), and three studies found tNAA unchanged after treatment with the SSRI paroxetine (37,38) or CBT (39). Among 14 studies comparing Glx in OCD versus healthy individuals, 2 of 8 reported significantly decreased Glx in ACC (31,40), and 1 of 3 reported increased Glx in OFC (35) (Figure 3).
The Neural Effects of Psychotropic Medications in Children and Adolescents
2012, Child and Adolescent Psychiatric Clinics of North America
This work was supported in part by the Miriam L. Hamburger Endowed Chair at Children's Hospital of Michigan, Wayne State University, and the State of Michigan Joe F. Young Sr. Psychiatric Research and Training Program, and by grants from the NIMH (MH01372, MH59299) and the National Alliance for Research on Schizophrenia and Depression.